NCT06492525View on ClinicalTrials.gov

A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Healthy
Interventions
DRUG

Ensartinib

225 mg oral dose on day 1 in period 1 and on day 18 in period 2

DRUG

Rifampicin

600 mg QD from day 9 to day 22 in period 2

DRUG

Itraconazole

200 mg QD from day 9 to day 19 in period 2

DRUG

Ensartinib

100 mg oral dose on day 1 in period 1 and on day 12 in period 2

Trial Locations (1)

310009

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY